The association of more than 140 genes with human photoreceptor degenerations, together with studies of animal models of these monogenic diseases, has provided great insight into their pathogenesis. Here we review the responses of the retina to photoreceptor mutations, including mechanisms of photoreceptor death. We discuss the roles of oxidative metabolism, mitochondrial reactive oxygen species, metabolic stress, protein misfolding, and defects in ciliary proteins, as well as the responses of Müller glia, microglia, and the retinal vasculature. Finally, we report on potential pharmacologic and biologic therapies, the critical role of histopathology as a prerequisite to treatment, and the exciting promise of gene therapy in animal models and in phase 1 trials in humans. 
INTRODUCTION
Over the past two decades, 148 genes and 186 loci have been associated with inherited photoreceptor degenerations (IPDs). The proteins encoded by the IPD genes are entirely diverse in their functions, including not only many required for phototransduction, but also structural and cytoskeletal proteins, RNA splicing factors, intracellular trafficking molecules, and proteins involved in phagocytosis and the regulation of intracellular pH. Upto-date documentation of IPD genes and loci, with references, continues at RetNet (http:// www.sph.uth.tmc.edu/RetNet/).
The genotypic and phenotypic heterogeneity of IPDs was examined in detail in the last Annual Review article on retinal degeneration (Pacione et al. 2003) and in more recent articles, as well (Daiger et al. 2007 , Hartong et al. 2006 ). In addition, as the prevalence of agerelated macular degeneration (AMD) has increased over the past decade, now affecting almost 9% of Americans 40 years of age or older; knowledge of the genetic contribution to this disease has also grown. Excellent reviews on the genetics and pathophysiology of AMD are available ( Jager et al. 2008 , Rattner & Nathans 2006 , Swaroop et al. 2007 ); we do not replicate that information here.
THE STRUCTURE OF THE MAMMALIAN RETINA: PHOTORECEPTORS, GLIA, AND VESSELS
The neural retina is composed of three morphologically discrete layers of cell bodies, bridged by synaptic terminals that guide the transmission of light-initiated neuronal and electrical impulses (Figure 1) . We briefly discuss not only the photoreceptors (PRs), but also retinal glia and the retinal vasculature, both of which have been increasingly implicated in the pathogenesis of IPDs.
The Photoreceptors
The PR layer is organized as a dense array of light-sensing cells in the retina, with cones (5% of total PRs) responsible for high intensity and contrast vision under photopic or bright light conditions, and rods (95% of total PRs) functioning under scotopic or dark-adapted conditions (Delyfer et al. 2004 , Pacione et al. 2003 . The conversion of visual cues to biochemical signals via phototransduction occurs within a
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maintain the viability of the PR cell (Young 1971) . The PR segment is a modified cilium that is connected to the cell body by a narrow <0.2 μm diameter connecting cilium overlying the basal body (Wolfrum & Schmitt 2000) . About 2000 rhodopsin molecules and 0.1 μm 2 of membrane must pass through the connecting cilium every minute because the outer segments account for most of the cell's surface area. The connecting cilium constantly regulates the influx and efflux of soluble and membranous proteins and lipids. It is crucial for all outer segment functions because it maintains the polarized distribution of all soluble and membrane-bound components.
Interestingly, the nuclei of rod PRs differ between nocturnal and diurnal animals: Nocturnal, unlike diurnal animals, exhibit an inverted pattern of chromatin organization compared with other cells in the body, with euchromatin at the nuclear periphery and heterochromatin at the center (Solovei et al. 2009 ). Solovei et al. postulated that this inverted pattern optimizes the channeling of light through rod PR bodies toward the rod outer segments.
Ciliary gene mutations and IPDs. The one area of genetics that has provided substantial new insight into the biology of the normal and mutant PR in recent years has been the frequent association of mutations in ciliary genes with IPD. Given the significance of the cilium to the PR, it is therefore not entirely surprising that over the past decade at least 38 genes associated with IPDs either have a ciliary or basal body location or are thought to influence ciliary function (Adams et al. 2007 , Lancaster & Gleeson 2009 ; http://www.sph.uth.tmc. edu/RetNet/) ( Table 1) . Mutations in these genes give rise to a wide range of IPD phenotypes, some of which also cause kidney, inner ear, brain, and developmental defects. There is genetic overlap between these disorders as well as evidence for epistatic interactions between loci (Beales et al. 2003) owing to the presence of multiprotein complexes within cilia, such as the BBSome and the Usher or RPGRIP1 interactomes. Different mutations in a single gene often cause more than one disorder, the most extreme example being NPHP6/CEP290 mutations, which can be associated with Leber congenital amaurosis, Joubert syndrome, nephronophthisis, Meckel syndrome (type 4), or Bardet-Biedl syndrome (type 14) ( Table 1) . Cilia are not just passive transport vehicles; they are also involved in at least five signaling cascades (Shh, canonical and noncanonical Wnt, calcium, PDGFRα), which may explain the variety of extraocular defects in the associated syndromes ( Table 1) .
Retinal Glia
In addition to the three major classes of neurons, the retina is also populated by three types of glia: Müller cells, microglia, and astrocytes. The importance of glia in conserving the structural and functional integrity of the retina is often underestimated or considered secondary to neuronal function. Rather than acting as bystanders, however, glia have recently been implicated as critical mediators in cell death and disease. Müller cells constitute 90% of all retinal glia (de Melo Reis et al. 2008 ) and extend radial processes from the base of the ganglion cell layer to the PR inner segments, ensheathing neurons along their path. In addition to serving a fundamental physiological function as optical fibers transmitting light while minimizing light scatter (Franze et al. 2007 ), Müller cells can be neuroprotective after retinal injury by releasing neurotrophic factors such as basic fibroblast growth factor (bFGF) and ciliary neurotrophic factor (CNTF) (Wilson et al. 2007) or antioxidants such as glutathione (Schutte & Werner 1998) . However, Müller cells may also contribute to neuronal cell death by dedifferentiating in response to prolonged or intense retinal injury. This dedifferentiation may impair neurotransmitter removal, as well as ion and water homeostasis (Bringmann et al. 2006) . Astrocytes provide many of the same functions as Müller glia, but are restricted almost entirely to the nerve fiber layer of the retina. Unlike astrocytes and Müller cells, the third glial subtype, microglia, may arise from myeloid tissue. Microglia play a central role in the elimination of neuronal debris and in the initiation of immunological signaling through the release of chemokines, cytokines, or neurotoxic factors (Langmann 2007) .
Retinal Vessels
Two independent vascular networks supply oxygen, glucose, and other nutrients to the retina. The central retinal artery proceeds from the optic nerve head, dividing into three capillary networks to deliver nutrients to the innermost layers. The choroidal blood vessels, separated from the RPE by Bruch's membrane, are vital to maintain the outer retina and PRs, have little capacity to autoregulate, and have an extremely high rate of blood flow. The oxygen content of the choroidal vascular bed is also unusually high: The arterio-venous difference in oxygen saturation is ∼35% in retinal vessels, whereas it is only 2%-4% in the choroid (Bill et al. 1983 ).
MECHANISMS OF PHOTORECEPTOR DEATH: HOW CELLS DIE IN IPDs
Programmed cell death (PCD) is an evolutionarily conserved feature of development, tissue turnover, and homeostasis found in all metazoans. PCD can be accomplished in four main ways-caspase-dependent and -independent apoptosis, autophagy, and the granzyme B pathway-although mixed forms also occur (Kroemer et al. 2009 , Tait & Green 2008 . Autophagy is currently classed as a PCD pathway, but in a physiological context it probably acts as a protective response to stress and death occurs only when protection fails (Boya & Kroemer 2008 ). Apoptosis is the major form of cell death in the nervous system. PR death during development is less prominent than in other retinal layers, but it involves caspase activation and is abolished or delayed in Bax/Bak double knockout or Bim single knockout mice (Donovan et al. 2006 , Hahn et al. 2003 . As developmental cell death declines, PRs become progressively less sensitive to proapoptotic stimuli, in parallel with the downregulation of caspases and proapoptotic Bcl-2-related proteins, making cells more prone to caspase-independent cell death or autophagy in the face of genetic insults (Donovan et al. 2006) .
The earlier literature emphasized the importance of classic apoptotic cell death in IPDs (Chang et al. 1993 , Doonan & Hunt 1996 , Portera-Cailliau et al. 1994 , Xu et al. 1996 . These studies relied heavily on the TUNEL assay, which was later shown to be nonspecific, because it labels both caspase-dependent and -independent apoptotic cells, as well as autolytic and necrotic cells (Colicos & Dash 1996 , Grasl-Kraupp et al. 1995 . More recent work has showed that at least some rodent models of retinal degeneration, including Prph2 rds/rds and Pde6b rd1/rd1 mice, involve caspase-independent apoptotic cell death (Doonan et al. 2005 , Lohr et al. 2006 , Paquet-Durand et al. 2007 , Rohrer et al. 2004 , Sancho-Pelluz et al. 2008 . Features of macroautophagy can also be present (Ahuja et al. 2008 , Doonan et al. 2005 .
THE RESPONSES OF THE RETINA TO PHOTORECEPTOR MUTATIONS
In this section, we focus principally on IPD genes within the broader context of the molecular and cellular pathogenesis of PR death. In many cases, the biological role of the corresponding wild-type protein is often unclear, and the link between the altered function of the mutant protein and the ultimate death of the PR is not evident. Nevertheless, significant insights are emerging.
Given the large number of genes associated with IPDs, it is not surprising that the biochemical, cellular, and clinical phenotypes observed in these disorders, and in animal models of them, are extremely heterogeneous. The singular sensitivity of PRs to environmental and genetic insults appears to result from many factors: exposure to light, high polyunsaturated fatty acid (PUFA) content, high oxidative metabolism, limited oxygen concentrations when functional demand rises and excessive oxygen exposure when it falls, the structurally narrow connecting cilium linking inner and outer segments, and the high protein and lipid turnover associated with outer segment renewal, among other factors (Travis 1998 ). The only common pathogenetic factor behind the diversity of the mutant genes associated with IPDs may be the shared ability to stress one of the most genetically vulnerable cells in the body.
High-throughput microarray gene expression analysis of the retinas in animal (mainly mouse) models of IPDs has been widely used to identify the secondary retinal genomic responses to the presence of a PR mutation. One of the most interesting outcomes of these studies has been the considerable degree of overlap in the resulting data sets; many of the same genes are differentially expressed in diverse IPD models. This finding suggests that IPDs share pathogenetic mechanisms, irrespective of the identity of the mutant gene or the clinical phenotype.
Mechanisms of Photoreceptor Death-Why Cells Die in IPDs
PR cell death appears to be a stochastic phenomenon in which the probability of cell death is increased by a broad range of cellular stresses, which may vary over time as the milieu interieur of the retina changes owing to both adaptive and maladaptive responses to PR loss. These stresses appear to converge on a final common death pathway, which is primarily apoptotic (whether caspase-dependent or -independent), but it remains unclear how this convergence takes place. Some of the proximal stresses and distal apoptotic triggers are now discussed.
The role of mitochondria and oxidative metabolism in photoreceptor death. PR cells have one of the highest rates of oxygen consumption in the body (Graymore 1960) , and oxygen consumption is particularly high in the parafoveal region of primates, where the rod density is highest (Ahmed et al. 1993 , Yu & Cringle 2005 . PR cell loss or reductions in energy-demanding activities, such as phototransduction, can lead to elevated tissue oxygen concentrations because choroidal blood vessels are not autoregulated by local oxygen levels. Increases in outer retinal oxygen concentrations have been confirmed in Mertk RCS/RCS rats (Yu et al. 2000) , Tg.Rho Pro23His rats , and CEP290 mutant cats (Padnick-Silver et al. 2006) . The attenuation of inner retinal arterioles (which do autoregulate) has been attributed to the high oxygen levels present in degenerating retinas (Noell 1953) . The oxygen toxicity hypothesis suggests that hyperoxia is a significant contributor to degeneration only in the later stages of disease progression (Stone et al. 1999) , but this proposal may underestimate the impact of small changes in oxygen, especially in the presence of light and potentially destructive retinoid derivatives.
Mitochondrial reactive oxygen species and PR death. Oxygen metabolism within mitochondria may also play an important and generic role in PR cell death. If each gene product and its associated pathway is evolutionarily well conserved-as visual pathways generally are-then the degeneration rates should be comparable across mammalian species, other factors being equal. The latter is clearly not the case because mammals differ markedly in size, metabolic rate, longevity, and other factors. Wright et al. (2004) explored this issue by contrasting rates of retinal degeneration caused by equivalent mutations in five genes (RHO, RDS, RPGR, TULP1, and ATXN7) across five mammalian species. This process was repeated for five inherited neurodegenerations affecting the brain (APP, SNCA, SOD1, HD, and PRNP). The results showed an inverse relationship (exponent 1.1 ± 0.2) between the degeneration rate and the maximum life span potential of the species. Two observations were particularly noteworthy: First, the relationship across genes and species is remarkably consistent; second, the degeneration rates differed by 10-to 100-fold. If such large differences in degeneration www.annualreviews.org • Inherited Photoreceptor Degenerationrate could be reproduced by genetic manipulation, the result would provide a truly worthwhile generic treatment intervention. The proposed explanation lay in the strong correlation between in vitro mitochondrial reactive oxygen species (ROS) formation and life span (Wright et al. 2004) . Other factors, such as basal metabolic rate, body mass index, phylogenetic group, and chance, were shown to be unlikely, a conclusion later reinforced by the work of Lambert et al. (2007) .
About 90% of cellular oxygen consumption occurs in mitochondria, where ROS are formed primarily as a by-product of oxidative phosphorylation (Murphy 2009 ). The in vivo rates of constitutive mitochondrial ROS formation are not accurately known because of their brief existence and low concentrations (Murphy 2009 ). Nevertheless, mammals such as the mouse clearly have high rates of constitutive mitochondrial ROS formation and high rates of retinal degeneration, whereas humans have correspondingly low rates, which probably reflects the differing selection pressures to extend longevity (Partridge 1997) .
This situation begs the question as to why mitochondrial ROS have such a powerful influence on cell death. One proposal is that gradual, age-related, and subliminal increases in constitutive (tonic) mitochondrial ROS formation influence retrograde (mitochondria-to-nucleus) and anterograde (nucleus-to-mitochondria) redox-sensitive signaling pathways and essentially set the probability of apoptosis accordingly for each cell (Wright et al. 2009 ). Such pathways have been well characterized in a wide variety of organisms and commonly involve ROS-induced posttranslational modification of critical thiols in enzymes such as phosphatases and a variety of transcription factors, which in turn affects both survival and proapoptotic signaling pathways (Janssen-Heininger et al. 2008 , Woodson & Chory 2008 . Mitochondria integrate cellular stress responses and control apoptotic cell death (Green & Kroemer 2004) , so the tonic regulation of cell death by interorganellar signaling could provide an additional level of long-term cellular quality control.
Two signaling pathways that influence PR cell death rates and contain known or potential redox-sensitive signaling components are p53 (Ali et al. 1998) , and HDAC4 (Chen & Cepko 2009 ), but many other pro-and antiapoptotic pathways are likely involved, depending on the type of PR stress. These pathways are proposed to set the balance of apoptotic signaling within cells, each of which has a unique redox history. The probability of apoptosis will vary among cells around the mean value for each genotype, species, and cell type. This proposal readily accounts for the observed kinetics of PR cell death and for its progressive nature (Clarke et al. 2000 , Clarke & Lumsden 2005 , Wright et al. 2009 ).
Intermediary metabolism, RNA processing, and photoreceptor death. A number of IPDs result directly or indirectly from metabolic stress. Metabolic stress-a disturbance of metabolic homeostasis-is generally one of the most common triggers for apoptotic cell death (Jin et al. 2007 ). One example is mutation in the nicotinamide adenine dinucleotide (NAD) specific mitochondrial enzyme isocitrate dehydrogenase (IDH3) (Hartong et al. 2008) . In most tissues, this reaction is catalyzed by the product of another gene, NADP-specific IDH2, suggesting that PRs have a particular requirement for IDH3, perhaps because its kinetic characteristics are more suited to the high substrate and cofactor concentrations found in PRs. Mutations in mitochondrial oxidative phosphorylation components can also give rise to syndromic forms of retinitis pigmentosa (RP) (e.g., MTATP6) (Childs et al. 2007 ). The retinal degeneration resulting from mutations in another metabolic enzyme, IMPDH1, which catalyzes a key step in guanine nucleotide biosynthesis, may be unrelated to this function however; instead it may involve loss of IMPDH's ability to regulate the translation of specific retinal mRNAs at polyribosomes, including the rhodopsin transcript (Mortimer et al. 2008) . This finding provides a strong connection to retinal degeneration because mutations influencing rhodopsin expression are a known cause of IPD (Daiger et al. 2007 , Kosmaoglou et al. 2008 ). This connection also raises the question of whether mutations in the ubiquitous precursor mRNA-processing factors PRPF31, PRPF8, PRPF3, and PAP1, which also cause IPDs, impose a similar type of cellular stress because of the unusual processing requirements of rhodopsin, which is produced at the rate of 10 6 -10 7 molecules/day/cell (Wolfrum & Schmitt 2000) , or because of other abundant PR-specific transcripts (Deery et al. 2002 , Mordes et al. 2007 ).
Protein misfolding in mutant photoreceptors. Oxidative and nitrosative stress associated with protein misfolding is probably the single most important cause of neurodegenerative brain disorders (Nakamura & Lipton 2007) . Some classes of mutation in the IPD genes CA4, BBS6, BEST1, EFMP1, RPE65, AIPL1, SCA7, ELOVL4, ABCA4, IMPDH1, RPGR, RS1, and RHO can be associated with protein misfolding, but many others will likely be identified in the future (Kosmaoglou et al. 2008) .
Rhodopsin accounts for 85%-90% of rod outer segment protein mass and may be the most extreme example of polarized protein distribution. The most common class of rhodopsin mutation (type II) involves the misfolding and retention of rhodopsin in the endoplasmic reticulum (ER) (Saliba et al. 2002) . This causes ER stress, which is detected by sensor proteins that can initiate an unfolded protein response (UPR) by activating adaptive signaling pathways (IRE1, ATF6, and PERK) (Lin et al. 2007 , Ron & Walter 2007 ). These pathways reduce the translation, enhance the folding capacity, or facilitate the clearance of misfolded proteins. Transgenic rats expressing the type II Rho Pro23His mutation show UPR activation and upregulation of protective chaperones that later decrease in abundance, in parallel with increased CCAAT/enhancer-binding protein homologous protein (CHOP) transcription factor expression, which induces transcriptional activation of proapoptotic genes (Lin et al. 2007) . A plausible sequence of events is the generation of a ROS signal by endoplasmic reticulum oxidase 1 (ERO1) as a result of futile attempts to correct high levels of misfolded protein, which in turn activates UPR signaling and apoptotic cell death pathways (Malhotra et al. 2008) .
Chaperones are essential for maintaining the continuous high throughput protein folding required by the activity of PR ribbon synapses. The cysteine string protein α (CSPα) cochaperone activates the ATPase activity of the HSC70 chaperone and is located in the presynaptic compartment of ribbon synapses (Tobaben et al. 2001) . CSPα knockout mice develop a rapidly progressive PR degeneration preceded by impaired presynaptic membrane traffic and synaptic terminal shrinkage (Schmitz et al. 2006) . The CSPα chaperone complex prevents the unfolding and subsequent toxicity of abundant synaptic proteins, possibly including certain SNAREs. The TULP1 protein has also been localized to ribbon synapses, as well as to PR connecting cilia, and compelling evidence from Tulp1 −/− mice now indicates that both ciliary trafficking and functional ribbon synapse defects contribute to the severity of the PR death in this model (Grossman et al. 2009 ).
The role of light in IPDs. Human ocular media transmit visible light to the retina in the range of 410-700 nm because the lens effectively absorbs most ultraviolet light (Wyszecki & Stiles 1982) . Visible and ultraviolet light are insufficiently energetic to ionize most biomolecules, but oxygen enhances the ionizing effects of light, especially in the presence of photosensitizers such as retinoids (Halliwell & Gutteridge 2007 , Quintiliani 1986 ). Light exposure can damage the PR and/or RPE in wild-type animals, and the damage is influenced by many factors (Organisciak et al. 2000) . In many IPDs, however, accumulating evidence indicates that there is increased retinal susceptibility to light damage, even at ambient light levels , Paskowitz et al. 2006 , Wu et al. 2009 ). Acute light damage may be due to the accumulation of all-trans retinal (Maeda et al. 2009 , Sun & Nathans 2001 , which readily generates singlet oxygen (Delmelle 1977, www.annualreviews.org • Inherited Photoreceptor Degeneration Lion et al. 1976 ). In addition, a small fraction of all-trans retinal molecules released by light spontaneously condenses to form either all-trans-retinal dimers or a variety of potentially toxic bis-retinoids including A2E (N-retinylidene-N-retinylethanolamine), iso-A2E, and A2-DHP-PE, which accumulate in RPE cells following disc phagocytosis (Sparrow et al. 1999 , Wu et al. 2009 ). These compounds absorb light maximally at the lower end of the visible spectrum (428-510 nm), and many are capable of generating ROS (Wu et al. 2009 ). Moreover, they are not easily degraded by lysosomal enzymes and are major constituents of RPE lipofuscin.
Stargardt disease caused by ABCA4 mutations is the IPD most clearly associated with increased formation of toxic bis-retinoids, owing to defective transport of all-trans retinal out of rod and cone outer segment discs by the ABCA4 flippase (Allikmets et al. 1997 , Travis et al. 2007 ). The predominantly macular location of the degeneration may relate to the photoreceptor/RPE ratio in this region of the retina (Snodderly et al. 2002) .
The relevance of all the above mechanisms to other genetically diseased retinas is still debated. Some retinal degenerations (e.g., Rho Thr4Arg ) are dramatically accelerated by light . Three different rhodopsin mutations are light sensitive, whereas another three are not, but at least seven other models of human retinal degeneration are exacerbated by light, protected by dark rearing, or both (Paskowitz et al. 2006) . Investigators have also reported clinically or histologically detected increases in RPE lipofuscin in a growing number of retinopathies, including mutations in GUCA1A, GUCY2D, RPGR, RIMS1, KCNV2, MERTK, RS1, and others of unknown genotype (Birnbach et al. 1994 , BuntMilam et al. 1983 , Robson et al. 2008 , Szamier & Berson 1977 . It therefore seems likely that a variety of genetic defects that either increase the formation of toxic retinoids or slow their removal may be exacerbated by light exposure. These defects include mutations that deform or destabilize discs, slow disc turnover, or inhibit their phagocytosis.
Lipid mediators of PR death.
Outer segments are lipid rich because of their tightly packed discs; the lipid content of outer segments is 15% of wet weight, compared with 1% in most cells (Whikehart 2003) . The amounts of very long chain PUFAs in outer segments are particularly high. Mutations in the ELOVL4 gene impair the elongation of C28 and C30 saturated and polyunsaturated fatty acids (Agbaga et al. 2008) and are associated with an autosomal dominant form of Stargardt disease (Bernstein et al. 2001 ). C28-C36 fatty acids are found together with another abundant PUFA, docosahexaenoic acid, predominantly in rod and cone outer segments where they are closely associated with opsin (McMahon & Kedzierski 2009 ). The disease mechanism in PRs with ELOVL4 mutations is related to selective deficiency of C28-C36 fatty acids, altered phototransduction, and excessive accumulation of the toxic retinoid A2E, for reasons that remain unclear (McMahon & Kedzierski 2009 ). This observation raises the possibility that dietary supplementation of long-chain PUFAs to type 3 Stargardt patients may be beneficial.
PR-specific responses in IPDs: Endothelin-2. It is absolutely remarkable that although PRs commonly carry the primary mutation in IPDs, the only PR gene identified to date that is exclusively differentially expressed in mutant PRs, and not in other retinal cell types, is Endothelin-2 (Edn2). The EDN2 peptide is one of three endothelins, vasoactive peptides implicated in diverse pathological processes from pulmonary hypertension to oncogenesis. The PR Edn2 mRNA increases in response to a spectrum of retinal insults, with significantly higher expression levels in models of IPD (Chen et al. 2004 , Cottet et al. 2006 , Rattner & Nathans 2005 , retinal detachment (Rattner & Nathans 2005 , Zacks et al. 2006 , increased intraocular pressure (Ahmed et al. 2004) , hyperoxia (Natoli et al. 2008) , and ischemia (Kamphuis et al. 2007) . Because the Endothelin B receptor (EDNRB) is concurrently upregulated in light damage, Rattner & Nathans (2005) postulated that EDN2 signals through EDNRB, which is localized to Müller cells. EDN2 signaling through Müller cell EDNRB may be protective because intravitreal administration of a selective EDNRB receptor agonist in a mouse model of IPD reduced PR death, whereas an EDNRB antagonist increased PR death (Joly et al. 2008) . In apparently contradictory studies, however, the dual EDNRA-EDNRB receptor antagonist Tezosentan reduced both caspase-3 cleavage in the outer nuclear layer (ONL) and glial fibrillary acidic protein (GFAP) expression in retinal extracts after light damage, suggesting a pathogenetic role for EDN2 (Torbidoni et al. 2006) .
Altogether, these studies indicate that the production of Edn2 mRNA by PRs is a general and perhaps universal response to PR stress. It is currently unclear whether the increased levels of the Edn2 message contribute to PR death or reduce it. If increased EDN2 is detrimental to PRs, blocking EDN2 signaling may be a novel therapeutic avenue for the treatment of IPDs because a myriad of pharmaceutical endothelin pathway antagonists exist and are being further developed.
The Response of Other Neuroretinal Cell Types to Photoreceptor Mutations
Although the PRs carry the mutation, many if not most of the changes in retinal gene expression in IPDs occur in glia. These secondary responses may influence the rate of PR death.
The Müller glia response. The apparently universal glial response to retinal insult is the increased expression of the proteins GFAP and VIMENTIN, which are regarded as the hallmarks of reactive gliosis. Gene expression studies have confirmed Gfap mRNA upregulation in IPDs (Hackam et al. 2004 , Rattner & Nathans 2005 , light damage (Chen et al. 2004 , Rattner & Nathans 2005 , and other models of stressinduced retinal injury (Kamphuis et al. 2007 , Natoli et al. 2008 (Nakazawa et al. 2007 , Verardo et al. 2008 .
A cardinal feature of the retinal response to a PR mutation or insult is increased expression of the transcription factor gene, Stat3, in Müller glia. STAT3 lies at the nexus of the IL-6 family cytokine signaling cascade (Hirano et al. 2000) . Several lines of evidence suggest that increased IL-6 family signaling in the retina, leading to increased STAT3 expression in Müller cells, is a protective response in IPDs and other retinal stresses. First, like Gfap, Stat3 mRNA is upregulated in both IPD and environmentally induced models of PR death (Hackam et al. 2004 , Rattner & Nathans 2005 . STAT3 expression in the INL is highest in the nuclei of Müller glia following light injury (Kassen et al. 2007 ). Second, exogenous delivery of the IL-6 family cytokine CNTF or its analog Axokine increases STAT3 expression in Müller glia (Kassen et al. 2009 , Peterson et al. 2000 and reduces PR death (Adamus et al. 2003 , Huang et al. 2004 , Tao et al. 2002 . However, CNTF can impair visual function when injected at high doses (McGill et al. 2007 ). Third, the expression of another IL-6 family cytokine, Lif, is also consistently upregulated in mouse models of IPD, with increased expression in a subset of Müller cells (Joly et al. 2008) . LIF may bind its receptor, LIFR, on the membrane of Müller cells (Sarup et al. 2004) in an autocrine fashion to activate STAT3. Intravitreal injection of LIF also rescues PRs (Ueki et al. 2008) , whereas genetic ablation of the Lif gene increased PR death in a mouse model of IPD ( Joly et al. 2008 ) and in light damage (Burgi et al. 2009 ). In summary, although STAT3 signaling can induce GFAP expression in Müller glia (Wang et al. 2002) , implying an exacerbation of reactive gliosis, the net effect of STAT3 signaling in IPDs appears to be protective of mutant PRs. However, it remains to be established that the IL-6-family induced increase in Müller cell STAT3 and the protective effect are causally linked. For example, in a light damage model in zebrafish, CNTF activated the mitogen-activated protein kinase (MAPK) pathway for neuroprotection and a STAT3 pathway for Müller cell proliferation (Kassen et al. 2009 ).
Increasing evidence suggests that the complement system, which is required to clear foreign particles and antigens and can trigger the release of cytokines and promote inflammation, is a significant participant in the retinal response to a PR mutation. First, transcripts for components of the complement cascade, including C4, C3, and C1q, are upregulated in the retina in mouse models of IPD (Demos et al. 2008 , Rattner & Nathans 2005 , Rohrer et al. 2004 ) and glaucoma (Ahmed et al. 2004 , Steele et al. 2006 . Moreover, polymorphisms in the genes for CFH, CFB, C3, and C2 are associated with AMD (Gold et al. 2006 , Haines et al. 2005 , Klein et al. 2005 , Rattner & Nathans 2006 , Yates et al. 2007 ). Second, the deletion of complement factor D, part of the alternative complement pathway, slowed PR death in a mouse light damage model (Rohrer et al. 2007b) , which is further evidence that the complement system has an influential role in the retinal response to injury. In contrast, loss of C1qa, a member of the classical complement activation pathway, or loss of B-and T-cell function did not alter the rate of PR death in a Pde6b rd1/rd1 model (Rohrer et al. 2007a) . In a mouse model of glaucoma, C1q expression was localized mainly to Müller glia and to the area of the retinal inner limiting membrane, which is partially composed of Müller cell end feet (Stasi et al. 2006) . Further study of the role of the complement system in mouse models will clarify the importance of this system in IPDs.
The microglia response to photoreceptor mutations. The microglia response in mouse models of IPDs can be either pathogenetic to or protective of PRs, apparently depending on the context. The canonical function of retinal microglia is to phagocytose dying PRs (Roque & Caldwell 1993) . A pathologic role in IPDs is suggested by the migration of activated retinal microglia to the degenerating PR layer and the release of neurotoxic factors, including TNF-alpha (Zeng et al. 2005 ) and perhaps IL-1beta (Ni et al. 2008 ). Moreover, minocycline treatment, which suppresses microglial activation, was protective of mutant PRs . In contrast, a protective role for microglia in IPDs is suggested by the secretion of the neurotrophic factors GDNF and CNTF, thereby increasing bFGF and BDNF expression in Müller cells and enhancing PR survival (Harada et al. 2002) . Bone marrowderived cells can be recruited into degenerating retina, differentiate into microglia, and migrate toward both regressing vessels and dying PRs. A reduction in the number of bonemarrow derived microglia increased PR death, and the activation of microglial progenitors by systemic administration of granulocyte colony stimulating factor (G-CSF) or erythropoietin resulted in a dramatic rescue of cone PRs (Sasahara et al. 2008 ). In conclusion, the evidence demonstrates that microglia are critically involved in the retinal response to PR mutations. Manipulation of the retinal microglia response in IPDs is a potential avenue for therapeutic intervention.
Cell-autonomous and non-cell-autonomous cell death in IPDs. Most PR mutations that cause IPDs also result in the non-cell-autonomous death of other cells. For example, RPE cells die in response to primary PR defects in Stargardt disease (Travis et al. 2007) , and cones die as a late consequence of primary rod PR loss. Humans spend most of their lives in ambient light levels that are well within the dynamic range of cones, but levels at which rods are saturated, so secondary cone loss accounts for much of the disability in IPDs. Various mechanisms have been proposed to explain secondary cone loss: (a) release of toxic compounds by dying rods (Ripps 2002) ; (b) loss of a rod-derived survival factor ); (c) microglia activation, which kills adjacent cones (Gupta et al. 2003) ; (d ) oxidative stress due to retinal hyperoxia (Stone et al. 1999) ; and (e) starvation of cones resulting from perturbed cone-RPE interactions due to rod loss (Punzo et al. 2009 ).
The retinal vasculature and IPDs. The temporal relationship between vascular and PR degeneration in the mouse was first examined by Blanks & Johnson (1986) , who concluded that PR death appears to precede vascular regression. Current hypotheses on the role of the vasculature in PR death therefore rest on the assumption that the vascular changes are secondary to decreased metabolic demand as the mutant PRs die and that increasing outer retinal oxygen concentrations, concomitant with the loss of PR outer segments and PR cell loss, result in the gradual ablation of retinal vessels (Yu & Cringle 2005) .
Recently, the association of vascular regression and PR death was examined by injecting hematopoietic stem cells into two mouse models of IPD. Otani et al. (2002) injected Lin − bone marrow-derived cells into neonatal mouse eyes and observed colocalization of the injected cells with developing vessels and astrocytes (Otani et al. 2002) . When Lin − bone marrow-derived cells were then intravitreally injected in two separate mouse models of IPD before the onset of PR death, the severe vascular regression normally associated with PR death was reduced. Concomitantly, a substantial rescue of cone PRs and mild restoration of retinal electroretinogram (ERG) responses were observed (Otani et al. 2004 ). The investigators remarked on the elongated appearance of the injected cells incorporated into the vascular network and their association with astrocytes, and they interpreted these features to be characteristic of endothelial cells. In contrast, Sasahara et al. (2008) demonstrated that transplanted bone marrow cells were predominantly microglial, in the same models of IPD. Regardless of whether vascular stability is primary or secondary to neuronal rescue, these results suggest that there is an important relationship between the fitness of the retinal vasculature and PR death in IPDs. The role of the vasculature in degeneration, although often overlooked, is therefore an avenue of research that deserves further exploration.
INHERITED PHOTORECEPTOR DEGENERATIONS: STEPS TOWARD TREATMENT
Pharmacologic and Biologic Interventions as Therapies for IPDs
A number of agents, including trophic factors, insulin, antioxidants, and vitamin A, slow PR death to a limited extent in IPDs (Stone et al. 1999) . The following synopsis focuses on novel factors and recent advances. Some of these approaches illustrate the non-cell-autonomous nature of IPDs. The heterogeneous nature of these therapeutic strategies suggests that multiple factors reduce the viability of the PRs in IPDs and that multifaceted pharmacological approaches may be required to facilitate PR rescue.
Antioxidants. The possibility that dying rods impose oxidative stress on adjacent cones was investigated by daily injection of an antioxidant mixture to the Pde6b rd1/rd1 mouse (Komeima et al. 2006) . In this RP mouse model, rod death is almost complete by postnatal day 21 (P21), after which cones die slowly over the subsequent two to three months. Treated animals showed a reduction in oxidative damage and a twofold increase in cone density compared with untreated controls. This effect was reproduced in two other mouse models of human RP (Komeima et al. 2007 ). Rod survival was also prolonged in the slower degenerating Pde6b rd10/rd10 model. Upregulation of antioxidant defenses by joint overexpression of SOD2 and catalase in mitochondria also protected cones (Usui et al. 2009 ). Increased superoxide concentrations were found during cone cell degeneration, and nitric oxide synthase inhibitors both reduced www.annualreviews.org • Inherited Photoreceptor Degenerationperoxynitrite-induced damage and increased cone survival in Pde6b rd1/rd1 mice (Komeima et al. 2008) .
The Pde6b rd1/rd1 mouse model of IPD is associated with severe oxidative stress due to calcium dysregulation (Farber 1995) . Individual antioxidants have little effect on disease progression, but feeding a mixture of antioxidants to mutant and control mice resulted in reduced apoptotic rod cell death (Sanz et al. 2007 ). The oxidizing environment of the outer retina appears therefore to be a significant factor in a range of retinal degenerations.
The deleterious effect of ROS is illustrated in one article that describes the use of cerium oxide nanoparticles (nanoceria) to scavenge reactive oxygen species in a rat light damage model (Chen et al. 2006a ). Intravitreal pretreatment with nanoceria preserved retinal ERG A-and B-wave amplitudes to 79% and 87% of controls, compared with 22% and 26% for vehicle.
Neurotrophins and survival signaling. The idea that cones die from loss of trophic support by rods has a long history (Faktorovich et al. 1990 , Steinberg 1994 , Streichert et al. 1999 . Four neurotrophic factors (bFGF, NGF, BDNF, CNTF) slow retinal degeneration in at least some animal models of RP. Retinal delivery of CNTF shows efficacy in 13 different animal models (MacDonald et al. 2007 ). The study employs encapsulated CNTF-expressing cells that are surgically implanted into the vitreous (Sieving et al. 2006) . The use of nanoparticles as a noninflammatory and nonimmunogenic genetic delivery technology, in addition to their use as a source of survival factors, is an interesting and potentially promising alternative to more conventional methods (Cai et al. 2009 ). A recent publication showed that vascular endothelial growth factor (VEGF) may promote PR survival in a paracrine fashion, with Müller-derived VEGF signaling through the VEGFR2 receptor on PRs. VEGF being protective has important implications for anti-VEGF-directed therapies for IPDs (Saint-Geniez et al. 2008 ). Punzo et al. (2009) analyzed nonautonomous cone degeneration in four different mouse models of human RP and found that activation of the insulin/mTOR pathway coincided with the activation of chaperone-mediated autophagy. When mice were treated with daily insulin injections for 4 weeks, cone survival increased by 20%. The authors proposed a model in which autophagy is induced mainly in response to nutrient starvation and only to a lesser extent by oxidative stress. Chen & Cepko (2009) recently identified another promising means of rescuing rods and cones using analysis of the nuclear corepressor histone deacetylase 4 (HDAC4) in the Pde6b rd1/rd1 mouse. Downregulation of HDAC4 expression increased the developmental apoptosis of PRs, whereas upregulation led to substantial neuroprotection from both developmental and degenerative PR death. The protective effect was due to retention of HDAC4 in the cytoplasm rather than the nucleus and was at least partly mediated by stabilizing HIF1α.
Rod-derived cone viability factor (RdCVF) also improves cone survival and function as shown by ERG in the rat Tg.Rho P23H model of RP , Yang et al. 2009 ). RdCVF is secreted by rods and is encoded by the nucleoredoxin-like 1(Nxnl1) gene, which is a member of the thioredoxin family. However, it lacks thiol oxidoreductase activity because it lacks the thioredoxin active site motif. Paradoxically, an alternatively spliced transcript that does contain a thioredoxin active site lacks trophic activity for cones (Fridlich et al. 2009 ).
Serial subretinal injections of human RdCVF protein into transgenic Rho
Pro23His rats increased cone density by 19%-20% compared with controls (Fridlich et al. 2009 ).
The promise of cell replacement therapy. Two recent studies have provided impressive evidence for the potential of cell replacement therapy for human IPDs. MacLaren et al. (2006) found that rod precursor cells transplanted into the subretinal space of rhodopsin null mice could integrate normally into the retina and differentiate into rod PRs, forming synaptic connections and leading to improved visual function. Successfully integrated PRs were unexpectedly derived only from postmitotic rod precursors harvested during a narrow window of development (postnatal days 1-7) and not from proliferating retinal progenitor cells. Lamba et al. (2009) subsequently demonstrated that human embryonic stem cells (hESCs) that had been directed to a retina cell fate in vitro (using a combination of a BMP inhibitor, a Wnt inhibitor, and IGF-1) migrated into wild-type mouse retinas after intraocular injection, localized to the appropriate layers, and expressed markers for differentiated cells, including both rod and cone photoreceptor cells (Lamba et al. 2009) (Figure 2 retina, and restored light response (Figure 2) . Together with the discovery that pluripotent stem cells (PSCs) can be induced from human embryonic fibroblasts (Woltjen et al. 2009) 
Understanding the Histopathology of Human IPDs: A Prerequisite to Treatment
For more than a century, clinicians described a group of progressive blinding retinal diseases termed RP (Bird 1981) . En face views of the ocular fundus in RP had abnormal pigmentation, changes in blood vessel caliber, and discoloration of the optic nerve head. Later, these diseases were recognized to follow classic genetic patterns.
En face fundus appearances of RP did not easily sort with genetic pattern and could not define disease mechanisms. A basic question remained: Which retinal cells are involved primarily in RP? Early histopathology of postmortem donor eyes from patients with RP pointed to PRs and the RPE as primary sites of degeneration . Noninvasive studies, such as ERG, confirmed that photoreceptor dysfunction was a major part of RP (Hartong et al. 2006) . Psychophysical measurement of rod-and cone-mediated vision has been a surrogate for retinal histopathology in RP for decades , Jacobson et al. 1986 Lyness et al. 1985; Massof & Finkelstein 1979 , 1981 Wald & Zeavin 1956 ).
Molecular genetic understanding of IPDs led to different directions for histopathological study ). For example, we learned about elucidation of the morphological basis of adRP phenotypes secondary to rhodopsin mutations , Li et al. 1994 ; proof that there are indeed excess short-wavelength cones relative to other cone subtypes and rods in the enhanced Scone syndrome caused by NR2E3 mutations (Milam et al. 2002) ; demonstration of thick sub-RPE deposits in late-onset retinal degeneration caused by C1QTNF5/CTRP5 mutation (Hayward et al. 2003 , Kuntz et al. 1996 , supporting the hypothesis that secondary vitamin A deprivation causes slowed rhodopsin regeneration in this disease ( Jacobson et al. 1995 ( Jacobson et al. , 2001 ; and the finding of photoreceptor cilial abnormalities in Usher syndrome retinas (Barrong et al. 1992 , Berson & Adamian 1992 , Hunter et al. 1986 ).
As scientific attention shifted toward identifying gene causation, molecular mechanisms were sought using in vitro methods and in vivo studies of genetically engineered or naturally occurring animals with gene mutations comparable to those in human diseases (Baehr & Frederick 2009 , Pacione et al. 2003 , Rattner et al. 1999 . Investigators could then advance to preclinical proof-of-concept studies and then human therapy. Identification of molecular causes in man and investigations of animal models, however, still left a gap in understanding whether human and animal diseases were sufficiently similar to warrant extrapolation from one to the other.
The gap was filled by the advent of optical methods to assess the living human retina, specifically optical coherence tomography (OCT). The laminar architecture of the retina in human IPDs could be visualized at all stages of disease. Imaging modalities that measure integrity of the RPE have provided further information (Cideciyan et al. 2007b , Gibbs et al. 2009 . A more complete understanding of human disease has now become possible using in vivo histopathology of the human retina taken together with clinical data, psychophysics, and ERGs and results from studies of animal models with comparable genotypes and phenotypes.
We illustrate cross-sectional images using OCT and colocalized rod and cone visual psychophysical results in different human retinal degenerations in Figure 3 . Normal human retinal laminar architecture (Figure 3a) has hypoand hyper-reflective layers with predictable relationships to histology , Jacobson et al. 2003 . The photoreceptor or ONL (Figure 3) 
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Figure 3
Retinal laminar architecture by in vivo microscopy in (a) a normal subject compared with (b-d ) three patients representing different molecularly defined retinal degenerative diseases with: Images are obtained using optical coherence tomography (OCT) across the vertical meridian through the fovea. OCTs are shown in grayscale with lowest reflectivity as black and highest reflectivity as white.
Brackets at left edge of normal scan define inner nuclear layer (INL, purple), outer nuclear layer (ONL, blue), inner and outer segment junction (IS/OS, yellow), and retinal pigment epithelium (RPE). Arrows point to ganglion cell layer (GCL) and nerve fiber layer (NFL). Inset (a, upper left) shows the location of the vertical retinal section on a schematic of the eye. Psychophysically determined rod ( gray) and cone (red ) sensitivities are shown above the scans. (d ) Yellow brackets at right edge of the coarsely laminated retina in a patient with CRB1-LCA shows regions of hyporeflectivity (deeper) and hyperreflectivity (more superficial) with uncertain layer identity.
the fovea, the site of highest cone density. The junction between inner and outer segments of the PRs (IS/OS) is deep to the ONL. The inner nuclear layer (INL), ganglion cell layer (GCL), and nerve fiber layer (NFL) are visible. Dramatic abnormalities are evident in Xlinked (XL) RP owing to mutation in the RPGR (retinitis pigmentosa GTPase regulator) gene , Wright & Shu 2007 (Figure 3b) . The ONL is thinned at the fovea and barely detectable past 4-6 mm eccentricity. Thinned ONL is accompanied by INL thickening; GCL and NFL are retained. Psychophysics indicates that only reduced cone function remains. These noninvasive results are consistent with the histopathology of RP and XLRP , Szamier et al. 1979 . Thickening of the INL is a marker for retinal remodeling in retinal degenerative diseases and has been documented in histopathology of animal models , Cideciyan et al. 2007a , Jacobson et al. 2006b ).
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USH: Usher syndromes
LCA: Leber congenital amaurosis
If this XLRP-RPGR patient was a candidate for a clinical treatment trial of, for example, a genebased and cone-specific therapy, then focal delivery to the central 10 mm of the retina may be a strategy ( Jacobson et al. 2006a) .
The Usher syndromes (USH) are syndromic forms of RP with hearing loss and possible vestibular abnormalities. Investigators have associated at least 12 loci with USH. The disease-causing genes encode proteins of different classes, thought to be integrated into a network (Maerker et al. 2008 , Williams 2008 . Testing hypotheses about USH pathogenetic mechanisms in the mammalian retina has been difficult because most mouse models of human USH genotypes have no retinal degeneration phenotype (Williams 2008 ). The onus is thus on human studies for information about USH retinal degeneration. We recently presented evidence for a common PR disease phenotype among human USH genotypes ( Jacobson et al. 2008a) .
Our in vivo histopathology in patients with USH1B (caused by mutations in MYO7A, Myosin VIIa) or USH1C showed the surprising finding that there can be disease stages in which patients have central regions of structurally and functionally normal retina. Adjacent regions show severe laminopathy and visual loss ( Jacobson et al. 2009b ). Unlike XLRP-RPGR, the USH1C retina illustrated (Figure 3c ) is normal in structure and function from the fovea to ∼4-6 mm eccentricity. At greater eccentricities, ONL thickness decreases, lamination becomes abnormal, and there is visual dysfunction. Degeneration of the central region will likely occur in later life, but we need to ponder whether we should be treating this normal retina with experimental therapies in early-phase safety trials (Hashimoto et al. 2007 , Williams 2008 .
Markedly abnormal retinal lamination is exemplified in a form of Leber congenital amaurosis (LCA). LCA is a group of childhood-onset retinal degenerations associated with many different genes , Stone 2007 . CRB1 (crumbs homolog-1) mutations account for ∼10% of LCA and also cause a rare form of RP. The Crumbs molecules are transmembrane proteins involved in apico-basal cell polarity and in the morphogenesis and maintenance of the retina (Gosens et al. 2008) . A CRB1-mutant retina is thickened, and there are coarse outer and inner laminar zones; a small cone-mediated island of vision corresponds with a limited island of foveal ONL (Figure 3d ). The abnormal retina in CRB1-LCA resembles that of immature normal retina, and the disease may have interrupted naturally occurring apoptosis ( Jacobson et al. 2003) . Are these retinas treatable with current therapeutic strategies? A retinal prosthesis may be helpful (Yanai et al. 2007) , pending evidence that the visual pathways from ganglion cells to cortex are sufficiently intact to warrant such an approach.
In summary, investigators can now study the many human retinal degenerations and the many disease stages of each with in vivo histopathology. Quantitative retinal structural data coupled with focal psychophysics can be used to elucidate mechanisms, perform natural history studies, compare human disease expression with those of animal models, and develop inclusion and exclusion criteria for clinical trials and outcomes of therapy. Advances will continue to occur in this technology with higherresolution instrumentation, wider-angle views, and eventual single-cell visualization; but this clinically feasible methodology should be used now to advance our understanding of IPDs, even if footnotes with revisions of interpretation will be necessary in the future.
From Proof-of-Concept Gene-Therapy Experiments to Human Clinical Trials
For decades, clinician researchers specializing in orphan IPDs played the disappointing role of disproving claims of treatment success from various sources and trying to discourage their patients from endangering their poorly functioning eyes and possibly their general health by rushing to accept unproven therapies.
The current era is more positive, given many successful proof-of-concept experiments using gene therapy in animal models of human IPDs. Early successes in the lab did not move to the clinic (Ali et al. 2000 , Bennett et al. 1996 . The autosomal recessive disease resulting in RPE65 (retinal pigment epithelium-specific-65-kDa) deficiency has mainly made this transition. This disorder interrupts function of the visual-retinoid cycle (Travis et al. 2007 ), visual pigment is not available to PRs through this key pathway (Figure 4a) , and vision is severely compromised. In a canine model of RPE65 deficiency, subretinal delivery of a gene-viral vector agent led to a remarkable activation of retinal and postretinal function (Acland et al. 2001) . Mice with RPE65 deficiency showed the same dramatic treatment effect (Bemelmans et al. 2006 , Chen et al. 2006b , Dejneka et al. 2004 , Lai et al. 2004 , Pang et al. 2006 . Following further proof-ofconcept studies, dose-response data, and toxicity testing (Acland et al. 2005; Jacobson et al. 2006a,b; Jacobson et al. 2005) , human gene therapy in RPE65-LCA seemed worthwhile to consider.
A pretrial concern was whether human and animal versions of RPE65 deficiency were identical. Human RPE65-LCA differed because there was considerable retinal degeneration from early life ( Jacobson et al. , 2007 ( Jacobson et al. , 2008b ( Jacobson et al. , 2009a . Did the remaining PRs in human RPE65-LCA show evidence of visual cycle dysfunction? Animals with Rpe65 deficiency have a disproportionate functional abnormality (i.e., severely reduced visual responses) when compared with the degree of retinal structural abnormality. Also, the animal diseases were not complicated by significant degeneration at the ages when treatment proved efficacious. A human trial would not be justifiable if the residual PRs in patients were behaving as if they were quantum-catch limited, the relationship of structure and function that is traditionally found in most other animal and human IPDs . Colocalized measurements of the ONL by OCT and photoreceptormediated function by psychophysics showed that RPE65-LCA patients did have disproportionate functional loss for the amount of PRs retained . These observations opened the door to consider a clinical trial more seriously, and investigators devised strategies to optimize delivery of the gene-vector to retinal areas with PRs ( Jacobson et al. , 2008b ( Jacobson et al. , 2009a .
Another pretrial concern involved cone PRs. The visual cycles of rod and cone PRs have differences, and the exact pathways are still debated (Travis et al. 2007 ). Mouse models with Rpe65 deficiency show early and severe cone PR loss. Was this also occurring in RPE65-LCA ( Jacobson et al. 2007) , and would the outcome of gene therapy be only rod-based efficacy? The canine model, unlike the mouse, did show improved cone function posttreatment (Acland et al. 2001 (Acland et al. , 2005 . A specific analysis of the cone foveas of RPE65-LCA patients over a wide age range indicated that there was definitely some loss of cone PRs from the earliest ages. Yet, some cones were remaining and functioning, albeit abnormal in function ( Jacobson et al. 2007) , which implied that residual cones in the fovea of humans with RPE65-LCA may be using an alternative visual cycle and that treating the fovea may not lead to fovea-specific increases in visual acuity. This rather important issue has still not been resolved despite some claims of increased visual acuity posttreatment; such results are equally consistent with extrafoveal rod or cone recovery.
Three contemporaneous clinical trials began at this time, and in 2008, all three studies reported preliminary results of safety and modest efficacy after uniocular subretinal injections of AAV2-RPE65 (Bainbridge et al. 2008 , Hauswirth et al. 2008 , Maguire et al. 2008 ; Figure 4b ). Cone and rod function increased ; Figure 4c,d ), but no foveal cone increase in function has been reported to date. Systemic and ocular safety was demonstrated, but the surgical technique is still one of the weaker elements in this multidisciplinary application of science to medicine. Foveal thinning and a macular hole have occurred in subfoveal injections (Hauswirth et al. 2008 , Maguire et al. 2008 . visual psychophysical improvement after treatment and its PR layer potential showed that the complex enzymatic and degenerative condition in the patients had been simplified by correction of the visual cycle abnormality . Unfortunately, what remained was the retinal degeneration, and its natural history is uncertain. An unexpected outcome was discovered and replicated in our treated patients . Patients self-reported that their vision was definitely brighter upon awakening compared with later in the day, after exposure to ambient light. This observation suggested that rod visual recovery could be better if the treated eye had more time to dark adapt. A slowed dark adaptation, implying a slowed visual cycle, was documented, and full adaptation took ∼8 h in treated retina compared with <1 h in normal retina. This effect has been persistent and unchanged for a year . The basis of the abnormality remains unknown. The practical consequence of the result is that therapeutic outcome of the trial should not be measured after bright light photography or ophthalmoscopy. Such clinical assessment tools should be reserved for times after rod-based outcomes are measured. Without thoughtful consideration of protocol, underestimates of efficacy or apparent variability will result. Also, for the patients to take full advantage of any recovered vision, they should be instructed not to expose their eyes to too much light; light exposure would bleach their newly acquired night vision and they would have to wait for hours to regain full sensitivity. After conversion of this complex human disease to a simpler retinal degeneration by gene therapy, we should also consider whether the newly acquired vision will subsequently be susceptible to the deleterious effects of light damage , Paskowitz et al. 2006 .
Questions about the longevity of safety and efficacy in gene therapy for RPE65-LCA have started to be addressed (Cideciyan et al. 2009a,b) . At one year postprocedure, our first cohort of patients continued to show no vectorrelated serious adverse events. Immunological assays to identify reaction to AAV2 capsid were unchanged from baseline, and clinical eye examinations remained as they were at three months postprocedure (Hauswirth et al. 2008 ). The dramatic improvements in visual sensitivity at 3 months were unchanged at 12 months. Specifically, the retinal extent and magnitude of rod and cone components of the newly enhanced vision remained the same. A fascinating self-report by one of the patients at one year postprocedure was also studied to understand its basis. The young adult noted for the first time that a numerical display on the dashboard of the family vehicle was readable. A visual acuity change was not present, so this was not simply slowly improving spatial resolution; visual sensitivity in the treated retinal region had also not varied. What had changed, however, was the fixation in this eye under different conditions: There was a slow and progressive movement of fixation over many months from the anatomical fovea to the treated retinal region. The region of therapy had become a preferred locus for use in this eye under certain conditions ).
The new visual experiences originating from the treated retinal area in our patient could be driving cortical adaptations (Butz et al. 2009 ). From a clinical perspective, this slow experience-dependent process in the treated eye may be accelerated by visual training (Taub et al. 2002) .
The teams of gene therapists who have initiated this new direction of treatment for IPDs have major obligations. Owing to the rarity of RPE65-LCA and other IPDs, there will continue to be limited numbers of patients to enroll in these trials. Therefore, we must understand as much as possible about each treated patient: not only what we have done but also what we could not accomplish with this novel therapy. Ignoring or minimalizing failure and complexities and publicizing only success is a trap we should avoid, although so many decades without treatment success makes everyone keen to announce recent progress. To date, the human studies in RPE65-LCA have been performed safely and with some efficacy. The daunting next major step for gene therapy trials is to devise treatment for primary PR degenerations. Unlike RPE65-LCA, these disorders include patients with expanses of useful and sometimes only moderately abnormal vision. High expectations for remarkable visual recoveries may have to be replaced by the less exciting but still useful outcome of slowed progression of these ultimately blinding disorders.
CONCLUDING REMARKS
The photoreceptor may have the distinction of being the most genetically vulnerable cell in mammals: Mutations in more than 140 genes have been associated with a single phenotype, cell death. The sensitivity of the PR to mutation provides a large number of perspectives from which the critical pathophysiological pathways culminating in PR cell death may be identified. Given the parsimony that generally underlies biology, however, we suggest that research be directed to identifying the pathophysiological processes common to most or all mutant PRs. These shared responses are most likely to lead to the deepest understanding of the molecular mechanisms that culminate in the "one hit" that ultimately kills the cell (Clarke et al. 2000 , Pacione et al. 2003 .
We have highlighted features of PR biology that likely contribute to its genetic susceptibility, including, for example, the inordinate demand for (a) PUFAs, (b) the visual pigment rhodopsin and other abundant proteins of the outer segment, and (c) high metabolic activity to sustain the rapid turnover rate of PR outer segments. Whether any one feature of PR biology is uniquely responsible for the susceptibility of PRs to mutation-induced cell death is unknown. Studies of mutant PRs have suggested that these cells are singularly vulnerable to a variety of stresses, including (a) the disruption of metabolic homeostasis, (b) oxidative stress associated with protein misfolding or elevated oxygen concentrations, and (c) constant exposure to light. Novel insights into the stresses imposed by mutation have been acquired from unbiased gene expression array studies, including a group of responses to a PR mutation that occurs commonly, perhaps even invariably, such as (a) the upregulation of Edn2 mRNA by mutant PRs, (b) the expression of intermediate filament proteins implied in the exacerbation of reactive gliosis, and (c) the activation of signaling cascades and upregulation of immune markers. Out of this complexity of altered gene expression, we must dissect the critical responses that promote cell death or survival. Is there a single biochemical event that, if prevented, would arrest PR death, or is the cell altered in so many ways that such simplicity is not possible? Determination of the significance of any change in a mutant PR will be greatly facilitated by genetic analyses (e.g. does a gene's loss of function improve PR survival?), and by examining the proteome of the mutant PR, which is now becoming technically feasible.
One can see several major outcomes of current IPD research. First, therapeutic opportunities will increase as we continue to reveal the pathophysiology of the mutant PR. For example, if the knockdown or ablation of a gene whose expression is increased in mutant retina prolongs mutant PR survival, then the small molecule-mediated inhibition of the activity of the corresponding gene product holds promise as a drug therapy. Second, the identification of responses that occur in all mutant PRs, irrespective of the mutant gene, may lead to general therapies. Even if the promise of gene replacement therapy is fully realized, the basic research and clinical trials that precede successful gene therapy take years, and a more general treatment for IPDs would fill an enormous therapeutic gap. Third, AAV-based or other forms of gene replacement are likely to continue to be valuable strategies to slow or arrest vision loss and in some diseases improve vision in patients with mutations in specific genes. Fourth, advances in the generation of induced pluripotent stem cells suggest that lost PRs may be replaced by genetically corrected PRs derived from, say, a patient's skin fibroblasts, thereby avoiding problems of immune rejection. Altogether, the future for treating this group of devastating inherited diseases has never looked brighter.
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